Sapience Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Team
    • Directors
    • Advisors
  • Our Approach
    • Overview
    • SPEARs™
    • PADS™ Platform
  • Pipeline
    • Overview
    • ST101
    • ST316
    • cJun Program
    • FoxP3 Program
    • Expanded Access
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Careers
  • Contact

Press Releases

News & Events

News & Events

  • Press Releases
  • Events
  • Publications
  • Presentations
  • Email Alerts
Jul 28, 2022 8:00am EDT

Sapience Therapeutics to Participate Virtually in Upcoming August Investor Conferences

Jun 03, 2022 8:00am EDT

Sapience Therapeutics Presents Phase 1 Data at ASCO 2022 Including Efficacy Proof-of-Concept with ST101 in Patients with Refractory Solid Tumors

Jun 02, 2022 8:00am EDT

Sapience Therapeutics Announces Expansion of Phase 2 Study Arm with ST101 in Patients with Recurrent Glioblastoma (GBM) Based on Confirmed Partial Response (PR)

May 31, 2022 8:00am EDT

Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactions

May 12, 2022 8:04am EDT

Sapience Therapeutics Announces Poster Presentation on ST101 Phase 1 Study Results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022

May 03, 2022 8:00am EDT

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma

Apr 11, 2022 10:00am EDT

Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways

Mar 31, 2022 8:00am EDT

Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs

Mar 15, 2022 4:05pm EDT

Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect

Mar 09, 2022 8:00am EST

Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next
RSS
© 2023 Sapience Therapeutics, Inc. All Rights Reserved.
linkedin
Policies Disclaimer Sitemap